Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
301584.SZ
SELLGet insider-trade alertsShanghai C&D INNOSTIC Medical Technology Group Co., Ltd. · Healthcare · China · $1.2B · Avg Vol: $9M/d
COMPANY DESCRIPTION
Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. provides comprehensive supply chain services and distribution for in-vitro diagnostic (IVD) products in China. The company partners with global and domestic IVD manufacturers to supply hospitals with reagents and equipment, utilizing an advanced hospital-integrated SPD (Supply, Processing, and Distribution) model. Its competitive moat is defined by its extensive healthcare network, regulatory compliance expertise, and high-efficiency logistics infrastructure.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 1.8B | 2.3B | 2.6B | 2.9B | 17.8% | 2.9B |
| EPS | — | 0.07 | 0.08 | 0.09 | 0.11 | 13.7% | 0.11 |
| Shares | — | 358.1M | 358.1M | 358.1M | 421.3M | +17.6% | 421.3M |
| Debt | 13.1M | 387.4M | 553.5M | 595.6M | 528.4M | 151.8% | 520.6M |
| Equity | — | 154.6M | 184.3M | 218.2M | 312.4M | 26.4% | — |
| Op CF | — | -92.5M | -55.2M | 24.2M | 110.2M | 355.0% | 150.4M |
| Inv CF | — | -6.1M | -13.9M | -17.7M | -22.8M | — | — |
| Fin CF | — | 163.9M | 134.4M | 18.2M | -79.2M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 301584.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 301584.SZ | Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd.(you) | $1.2B | 29 | SELL |
| AHG | Akso Health Group | $1.3B | 12 | STRONG SELL |
| 000950.SZ | C.Q. Pharmaceutical Holding Co., Ltd. | $1.3B | 51 | HOLD |
| 002589.SZ | Realcan Pharmaceutical Group Co., Ltd. | $543M | 39 | HOLD |
| 600739.SS | Liaoning Cheng Da Co., Ltd. | $2.2B | 56 | HOLD |
| 2656.HK | 160 Health International Limited | $419M | 5 | STRONG SELL |
| 0314.HK | Sipai Health Technology Co., Ltd. | $119M | 18 | STRONG SELL |
| 600056.SS | China Meheco Group Co., Ltd. | $1.9B | 80 | BUY |
| 301015.SZ | Qingdao Baheal Medical INC. | $1.5B | 86 | STRONG BUY |
| 1931.HK | ETHK Labs Inc. | $125M | 14 | STRONG SELL |
Peer medians: ROE 4.8% · P/E 26.5x · Gross margin 52.5%